Stock Track | Hims & Hers Surges on Strong Q3 Results, Growth Prospects

Stock Track

2024-11-06

Shares of Hims & Hers Health Inc. (HIMS) soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.

The company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.

Adding to the positive sentiment, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a popular diabetes and weight loss drug, on its platform by 2025. This move is expected to further boost the company's revenue and growth prospects in the lucrative weight management market.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1155669705"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155669705\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1155669705?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 16:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155669705","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Surges on Strong Q3 Results, Growth Prospects","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.</p>\n\n<p>The company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.</p>\n\n<p>Adding to the positive sentiment, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a popular diabetes and weight loss drug, on its platform by 2025. This move is expected to further boost the company's revenue and growth prospects in the lucrative weight management market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Surges on Strong Q3 Results, Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Surges on Strong Q3 Results, Growth Prospects\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-06 16:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (HIMS) soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.</p>\n\n<p>The company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.</p>\n\n<p>Adding to the positive sentiment, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a popular diabetes and weight loss drug, on its platform by 2025. This move is expected to further boost the company's revenue and growth prospects in the lucrative weight management market.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1155669705","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155669705","pubTimestamp":1730881727,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc.  soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.The company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.Adding","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票赛道Hims&Hers因强劲的第三季度业绩和增长前景而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) soared 5.33% on November 6, 2024, fueled by the telehealth platform's impressive third-quarter earnings and promising growth plans.\nThe company reported a remarkable 77% year-over-year increase in revenue to $401.6 million for the third quarter of 2024, surpassing analyst expectations. The robust performance was driven by strong demand for Hims & Hers' personalized weight loss solutions, particularly its compounded versions of GLP-1 drugs like semaglutide.\nAdding to the positive sentiment, Hims & Hers announced plans to launch a generic version of Novo Nordisk's liraglutide, a popular diabetes and weight loss drug, on its platform by 2025. This move is expected to further boost the company's revenue and growth prospects in the lucrative weight management market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}